a very likely reason that full enrollment here at the end has been so slow is that amrn does not want "bad luck" ahead of interim. say you complete enrollment in the next 2 weeks (they could if they wanted to), but unluckily, 10 guys that just enrolled and were getting vascepa, had heart attacks the next day after entering the trial. that would skew results against the company without enough time for things to normalize. after interim, and if there is no stop, expect the trial to finish enrollment literally in a flash.